Cresset Asset Management LLC Purchases 3,535 Shares of Eli Lilly and Company $LLY

Cresset Asset Management LLC grew its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 5.4% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 68,718 shares of the company’s stock after purchasing an additional 3,535 shares during the quarter. Cresset Asset Management LLC’s holdings in Eli Lilly and Company were worth $53,569,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of LLY. Braun Bostich & Associates Inc. lifted its position in shares of Eli Lilly and Company by 2.5% during the 2nd quarter. Braun Bostich & Associates Inc. now owns 527 shares of the company’s stock valued at $411,000 after buying an additional 13 shares in the last quarter. Rise Advisors LLC increased its holdings in Eli Lilly and Company by 1.8% in the 2nd quarter. Rise Advisors LLC now owns 732 shares of the company’s stock valued at $571,000 after acquiring an additional 13 shares during the last quarter. Occidental Asset Management LLC lifted its position in shares of Eli Lilly and Company by 0.7% in the second quarter. Occidental Asset Management LLC now owns 1,966 shares of the company’s stock worth $1,533,000 after buying an additional 13 shares in the last quarter. New Insight Wealth Advisors boosted its position in shares of Eli Lilly and Company by 3.4% during the 2nd quarter. New Insight Wealth Advisors now owns 394 shares of the company’s stock valued at $307,000 after acquiring an additional 13 shares during the last quarter. Finally, Dash Acquisitions Inc. lifted its position in Eli Lilly and Company by 2.8% during the second quarter. Dash Acquisitions Inc. now owns 485 shares of the company’s stock valued at $387,000 after purchasing an additional 13 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have issued reports on LLY. Cantor Fitzgerald restated an “overweight” rating on shares of Eli Lilly and Company in a research report on Monday. Daiwa Capital Markets boosted their target price on Eli Lilly and Company from $700.00 to $940.00 in a research report on Monday, November 10th. Morgan Stanley increased their price target on Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the company an “overweight” rating in a report on Monday, November 24th. Wolfe Research raised their price target on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the stock an “outperform” rating in a research report on Wednesday. Finally, Loop Capital set a $950.00 price objective on shares of Eli Lilly and Company in a research report on Monday, November 10th. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,087.32.

Eli Lilly and Company Stock Down 2.1%

Shares of LLY opened at $1,011.74 on Friday. The firm has a fifty day moving average price of $913.15 and a 200-day moving average price of $807.53. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. The firm has a market capitalization of $956.48 billion, a P/E ratio of 49.50, a P/E/G ratio of 1.15 and a beta of 0.37. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,111.99.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The firm’s revenue for the quarter was up 53.9% on a year-over-year basis. During the same quarter last year, the business posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be issued a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s payout ratio is presently 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.